[go: up one dir, main page]

DE69739828D1 - Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums - Google Patents

Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums

Info

Publication number
DE69739828D1
DE69739828D1 DE69739828T DE69739828T DE69739828D1 DE 69739828 D1 DE69739828 D1 DE 69739828D1 DE 69739828 T DE69739828 T DE 69739828T DE 69739828 T DE69739828 T DE 69739828T DE 69739828 D1 DE69739828 D1 DE 69739828D1
Authority
DE
Germany
Prior art keywords
agents
ppargamma
methods
pharmaceutical compositions
tumor growth
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739828T
Other languages
English (en)
Inventor
Bruce M Spiegelman
Soner Altiok
Elisabetta Mueller
Pasha Serraf
Peter Tontonoz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dana Farber Cancer Institute Inc
Original Assignee
Dana Farber Cancer Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/923,346 external-priority patent/US6552055B2/en
Application filed by Dana Farber Cancer Institute Inc filed Critical Dana Farber Cancer Institute Inc
Application granted granted Critical
Publication of DE69739828D1 publication Critical patent/DE69739828D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE69739828T 1996-12-11 1997-12-11 Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums Expired - Lifetime DE69739828D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76655396A 1996-12-11 1996-12-11
US08/923,346 US6552055B2 (en) 1996-12-11 1997-09-04 Methods and pharmaceutical compositions for inhibiting tumor cell growth

Publications (1)

Publication Number Publication Date
DE69739828D1 true DE69739828D1 (de) 2010-05-12

Family

ID=27117766

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69726182T Expired - Lifetime DE69726182T2 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor
DE69739828T Expired - Lifetime DE69739828D1 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische Zusammensetzungen zur Inhibition des Tumorwachstums

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69726182T Expired - Lifetime DE69726182T2 (de) 1996-12-11 1997-12-11 Methoden und pharmazeutische zusammenstellungen zur wachstumsverhinderung von tumorzellen enthaltend einen ppar-gamma agonisten und einen map kinase inhibitor

Country Status (8)

Country Link
US (1) US7635708B2 (de)
EP (2) EP0948324B1 (de)
JP (2) JP4549443B2 (de)
AT (2) ATE253903T1 (de)
AU (1) AU5601898A (de)
CA (1) CA2274756C (de)
DE (2) DE69726182T2 (de)
WO (1) WO1998025598A2 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998029120A1 (en) * 1996-12-31 1998-07-09 The Salk Institute For Biological Studies Treatment of liposarcomas using a combination of thiazolidinediones and retinoid x receptor selective agonists
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
WO1999048529A1 (en) * 1998-03-20 1999-09-30 Warner-Lambert Company Retinoid-glitazone combinations
US7045519B2 (en) 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
CA2350599A1 (en) * 1998-11-20 2000-06-02 Genentech, Inc. Method of inhibiting angiogenesis
GB9908647D0 (en) * 1999-04-15 1999-06-09 Smithkline Beecham Plc Novel compounds
GB9917405D0 (en) * 1999-07-23 1999-09-22 Univ Dundee Methods of treatment and drug screening methods
WO2001052789A2 (en) 2000-01-20 2001-07-26 The Brigham And Women's Hospital, Inc. PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF
NO20003591L (no) * 2000-07-13 2002-01-14 Thia Medica As Fettsyreanaloger for behandling av kreft
WO2002013864A1 (fr) * 2000-08-16 2002-02-21 Sankyo Company, Limited Preparation medicinale de prevention et traitement du cancer
EP1365796A2 (de) 2000-09-01 2003-12-03 Van Andel Institute Hemmung des mitogenaktivierten proteinkinase (mapk)-weges: eine selektive therapeutische strategie gegen melanome
JP2004525168A (ja) 2001-04-06 2004-08-19 エフ．ホフマン−ラ　ロシュ　アーゲー 腫瘍の成長を抑制もしくは減少するための単独または他の治療薬との組合わせでのチアゾリジンジオン
US6756399B2 (en) 2001-06-29 2004-06-29 The United States Of America As Represented By The Department Of Health And Human Services Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents
US20040197834A1 (en) * 2001-07-20 2004-10-07 Francois Gervais Method to increase expression of pgd2 receptors and assays for identifying modulators of prostaglandin d2 receptors
WO2003032988A1 (fr) * 2001-10-17 2003-04-24 Sankyo Company, Limited Composition pharmaceutique
JP5249484B2 (ja) * 2001-12-11 2013-07-31 第一三共株式会社 医薬組成物
WO2003053440A1 (fr) * 2001-12-11 2003-07-03 Sankyo Company, Limited Composition medicinale
WO2003082865A1 (fr) * 2002-04-01 2003-10-09 Sankyo Company, Limited Composition médicinale antitumorale
JP2004083574A (ja) * 2002-06-25 2004-03-18 Sankyo Co Ltd 利尿剤及びペルオキシソーム増殖因子活性化受容体（ＰＰＡＲ）γ活性化剤を含有する医薬組成物
TW200403055A (en) * 2002-06-25 2004-03-01 Sankyo Co Pharmaceutical composition of a peroxisome proliferator-activated receptor (PPAR) gamma atcivetor and a diuretic
HU0301358D0 (en) 2003-05-14 2003-07-28 Debreceni Egyetem Novel use of ppargamma agonists
WO2006074147A2 (en) 2005-01-03 2006-07-13 Myriad Genetics, Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
AU2004253967B2 (en) * 2003-07-03 2010-02-18 Cytovia, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
EP1555021A1 (de) * 2004-01-16 2005-07-20 National Health Research Institutes Kombinationen eines Mevalonat-Weg-Inhibitoren und eines PPAR-Gamma-Agonisten für die Behandlung von Krebs
JP4556511B2 (ja) * 2004-06-25 2010-10-06 ソニー株式会社 １５ｄ−ＰＧＪ２、及び、１５ｄ−ＰＧＪ２を用いた方法
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
CA2600712A1 (en) * 2005-03-14 2006-09-21 Immunomedics, Inc. Methods of treating cancer using ppar-gamma antagonists
EP1865954A4 (de) 2005-03-21 2010-12-15 Metabolex Inc Verfahren zur vermeidung von ödem bei der behandlung oder prävention von auf ppar gamma ansprechenden erkrankungen einschliesslich krebs
BRPI0616454A2 (pt) 2005-09-30 2011-06-21 Vitae Pharmaceuticals Inc métodos de tratamento de cáncer
WO2007061094A1 (ja) 2005-11-28 2007-05-31 Senju Pharmaceutical Co., Ltd. Ｐｐａｒアゴニスト含有医薬
RU2449789C2 (ru) 2007-05-21 2012-05-10 Сэндзю Фармасьютикал Ко., Лтд. Лекарственное средство, содержащее prarδ агонист
WO2010070379A1 (en) * 2008-12-17 2010-06-24 Centre National De La Recherche Scientifique Rxr-ppargamma agonist/growth factor inhibitor combination therapy for inducing apoptosis and the treatment of cancer
CA2839102A1 (en) 2011-06-29 2013-01-03 The Penn State Research Foundation Compositions, methods and kits for treating leukemia
AU2012352149B2 (en) 2011-12-13 2017-06-01 Io Therapeutics, Inc. Autoimmune disorder treatment using RXR agonists
US10653650B2 (en) 2011-12-13 2020-05-19 Io Therapeutics, Inc. Treatment of diseases by concurrently eliciting remyelination effects and immunomodulatory effects using selective RXR agonists
JP5987175B2 (ja) * 2012-07-02 2016-09-07 学校法人福岡大学 乳癌，胃癌及び卵巣癌等に対する制癌剤
CA2890086C (en) 2012-11-05 2022-05-31 Commissariat A L'energie Atomique Et Aux Energies Alternatives (Cea) Combination of an anti-cancer agent such as a tyrosinekinase inhibitor and a stat5 antagonist preferably a thiazolid nedione, for eliminating hematologic cancer stem cells in vivo and for preventing hematologic cancer relapse
CA2958771A1 (en) * 2014-09-08 2016-03-17 Dana-Farber Cancer Institute, Inc. Methods of treating cancer
EP3368081A4 (de) * 2015-10-31 2019-06-19 IO Therapeutics, Inc. Behandlung von krebs mit kombinationen aus rxr-agonisten und schilddrüsenhormonen
CN115433716A (zh) 2015-10-31 2022-12-06 Io治疗公司 使用rxr激动剂和甲状腺激素的组合治疗神经系统紊乱
WO2017151836A1 (en) * 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
CN115227825A (zh) 2016-03-10 2022-10-25 Io治疗公司 Rxr激动剂和甲状腺激素在制备用于治疗自身免疫疾病的药物中的用途
KR20180121983A (ko) 2016-03-10 2018-11-09 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 근육 질환의 치료
EP3684348A4 (de) 2017-09-20 2021-08-18 IO Therapeutics, Inc. Behandlung von krankheiten mit estern von selektiven rxr-agonisten
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
CA3191858A1 (en) * 2020-09-08 2022-03-17 National University Corporation Ehime University Fluorescent dye and method for detecting tumor cells
CA3242047A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
US5605930A (en) * 1991-10-21 1997-02-25 The United States Of America As Represented By The Department Of Health And Human Services Compositions and methods for treating and preventing pathologies including cancer
DE10199033I2 (de) * 1992-04-22 2003-01-09 Ligand Parmaceuticals Inc Retinoid-x Rezeptor selektive Verbindungen
US5552271A (en) 1992-06-16 1996-09-03 La Jolla Cancer Research Foundation RXR homodimer formation
US5466861A (en) 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5521202A (en) 1993-04-07 1996-05-28 Taiho Pharmaceutical Co., Ltd. Thiazolidine derivatives and pharmaceutical compositions containing the same
EP0724636A1 (de) 1993-10-22 1996-08-07 Ligand Pharmaceuticals, Inc. Menschlichen "peroxisomen proliferator" aktivierte rezeptor
WO1995018533A1 (en) 1994-01-04 1995-07-13 The Trustees Of The University Of Pennsylvania Methods and compounds affecting adipocyte differentiation and obesity
US5514821A (en) 1994-05-27 1996-05-07 Ligand Pharmaceuticals Incorporated Ring-labeled retinoids and intermediates, and methods for their synthesis and use
US5594015A (en) * 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
EP0769146A2 (de) 1994-07-01 1997-04-23 Ligand Pharmaceuticals, Inc. Screening von "nuc" inhibitoren
AU2952695A (en) 1994-07-01 1996-01-25 Salk Institute For Biological Studies, The Mammalian peroxisome proliferator-activated receptors and uses thereof
AU696501B2 (en) 1994-08-10 1998-09-10 F. Hoffmann-La Roche Ag Retinoic acid x-receptor ligands
US6022897A (en) * 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
JPH11511004A (ja) * 1995-05-04 1999-09-28 シティ・オブ・ホープ ヒト白血球１２−リポキシゲナーゼおよび疾病状態の病因でのその役割
US5939442A (en) * 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
RU2158607C2 (ru) * 1995-07-03 2000-11-10 Санкио Компани Лимитед Лечение артериосклероза и ксантомы
ES2216062T3 (es) * 1995-09-18 2004-10-16 Ligand Pharmaceuticals, Inc. Tratamiento de la niddm con agonistas del rxr.
CA2235036A1 (en) * 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5814647A (en) 1997-03-04 1998-09-29 Board Of Regents, The University Of Texas System Use of troglitazone and related compounds for the treatment of the climacteric symptoms

Also Published As

Publication number Publication date
JP4550133B2 (ja) 2010-09-22
US20030144330A1 (en) 2003-07-31
ATE462433T1 (de) 2010-04-15
JP2009063566A (ja) 2009-03-26
WO1998025598A2 (en) 1998-06-18
JP2001510462A (ja) 2001-07-31
AU5601898A (en) 1998-07-03
DE69726182T2 (de) 2004-08-12
EP0948324B1 (de) 2003-11-12
CA2274756A1 (en) 1998-06-18
EP1410799A1 (de) 2004-04-21
ATE253903T1 (de) 2003-11-15
DE69726182D1 (de) 2003-12-18
EP0948324A2 (de) 1999-10-13
JP4549443B2 (ja) 2010-09-22
US7635708B2 (en) 2009-12-22
WO1998025598A3 (en) 1998-07-30
EP1410799B1 (de) 2010-03-31
CA2274756C (en) 2007-03-13

Similar Documents

Publication Publication Date Title
ATE462433T1 (de) Methoden und pharmazeutische zusammensetzungen zur inhibition des tumorwachstums
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
DE69830072D1 (de) Radioaktive zusammensetzungen zur behandlung von prostatatumoren
ATE308880T1 (de) Verfahren zur erhöhung der biologischen effektivität von zusammensetzungen zur pflanzenbehandlung
EP0986382A4 (de) Raf kinase hemmer
DE59903921D1 (de) Indolderivate und deren verwendung zur behandlung von malignen und anderen, auf pathologischen zellproliferationen beruhenden erkrankungen
DE69916035D1 (de) Vorrichtung zur behandlung von halbleiterscheiben
PT1233958E (pt) Inibidores de histona desacetilase
DE3674308D1 (de) Biozide zusammensetzungund verfahren zur behandlung von wasser.
IL126557A0 (en) Quinoline carboxamides as tnf inhibitors and as pde-iv inhibitors
DE3683374D1 (de) Mikrobielle zusammensetzungen und verfahren zur behandlung vom boden.
DE69921156D1 (de) Verwendung von 5ht-6 antagonisten zur behandlung adhd
BR9509145A (pt) Polímeros de ioneno solúvel em água método para preparação de um polimerode ioneno composto método para destruir microorganismos ou pestes método para tratar infecções de úbere de gado leiteiro e fertilizante
NO985652L (no) Anvendelse av naaladaseinhibitorer ved behandling av kreft
IL197686A0 (en) Pharmaceutical compositions containing alpha-4 integrin antagonists and uses thereof in the treatment of multiple myeloma and diseases associated therewith
AR024138A1 (es) Inhibidores de la proliferacion celular
DE3779930D1 (de) Zusammensetzungen zur oberflaechenbehandlung, polymere dafuer und verfahren zur oberflaechenbehandlung.
ATE292801T1 (de) Verfahren zum screening von inhibitoren von asp2
ATE122373T1 (de) Inhibierende behandlung von aluminium-pigmenten.
NO20010956L (no) Modulering av hukommelseseffektor T-celler samt midler for dette
DE60045247D1 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
IS3037A7 (is) Útbúnaður til að nema burtu yfirborð af vöðvavef dýra, einkum fiskflaka
DE69902127D1 (de) Histon beinhaltende zusammenstellung zur behandlung von rheumatischer arthritis
DE3581703D1 (de) Verfahren und vorrichtung zur biologischen behandlung von wasser, insbesondere zur denitrifikation von rohwasser zur trinkwasseraufbereitung.
NO20003848D0 (no) FremgangsmÕte ved behandling av folikkulært lymfom ved anvendelse av inhibitorer for lymfotoksin (LT)-veien

Legal Events

Date Code Title Description
8364 No opposition during term of opposition